Biotech investors are heading into the year’s biggest dealmaking event with a renewed sense of optimism after more than two years of layoffs and shrinking stock prices. The tide has shifted in just a few months as large drugmakers open their wallets again for acquisitions, in some cases paying more than double a company’s stock price for promising treatments. Firms developing weight-loss drugs, targeted cancer therapies and other buzzy medicines are all hopeful that they’ll be next in line.
Read the full article: Ozempic Challengers, Immunology Firms Line Up for Rebound in M&A //
Source: https://www.themiddlemarket.com/news-analysis/ozempic-challengers-immunology-firms-line-up-for-rebound-in-ma